Pertuzumab: Phase III started

Chugai disclosed in its 1Q12 earnings presentation that in April it began a double-blind, placebo-controlled, international Phase III trial to compare IV pertuzumab plus Herceptin trastuzumab and standard chemotherapy vs. Herceptin plus standard chemotherapy in about 3,806 patients who had breast cancer surgery. Patients in the pertuzumab arm will receive an initial 840 mg loading dose and then 420 mg pertuzumab every 3 weeks for 1 year. All patients will receive an 8 mg/kg loading dose of Herceptin and then a 6 mg/kg dose every 3 weeks for 1 year plus 6-8 cycles of standard chemotherapy. ...